Androstenedione is the preferred androgen source in hormone refractory prostate cancer--letter

Clin Cancer Res. 2014 Sep 15;20(18):4971. doi: 10.1158/1078-0432.CCR-14-1123.

Authors

Nima Sharifi¹, Richard J Auchus²

Affiliations

¹ Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio. sharifn@ccf.org.
² Division of Metabolism, Diabetes, and Endocrinology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

PMID: 25225065
DOI: 10.1158/1078-0432.CCR-14-1123

No abstract available

Publication types

Letter

MeSH terms

Androgen Antagonists / therapeutic use
Androgens / metabolism*
Androstenedione / metabolism*
Drug Resistance, Neoplasm / physiology*
Humans
Male
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / metabolism*

Substances

Androgen Antagonists
Androgens
Androstenedione